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Some mechanisms have been proposed to explain the role of bradykinin on glucose homeostasis and some studies reported that
the BDKRB2 +9/−9 polymorphism was associated to the transcriptional activity of the receptor. In this scenario, the main aim of
this study was to evaluate the association of the BDKRB2 +9/−9 polymorphism with diabetes mellitus risk in the Brazilian general
population. This study included 1,032 subjects of the general urban population. Anthropometrical, blood pressure, biochemical,
and genotype analyses for the BDKRB2 +9/−9 bp insertion/deletion polymorphism were performed. Individuals carrying +9/+9
or +9/−9 genotypes had higher glucose values (84.5mg/dL versus 80.6mg/dL, resp.) and higher frequency of diabetes mellitus
(7.6% versus 3.6%, resp.) compared to individuals carrying −9/−9, adjusting for age and gender. In addition, higher diabetes
mellitus risk was associated to presence of the +9/+9 or +9/−9 genotypes (OR= 1.91; 95% CI= 1.09–4.19; P = 0.03). Our data
suggest that the BDKRB2 +9/-9 polymorphismmay act as a genetic modulator of glucose homeostasis. It was previously associated
to insulin sensitivity, glucose uptake, and insulin secretion, and, in this study, data suggest that the polymorphism may increase
susceptibility to chronic metabolic conditions such as diabetes in the Brazilian population.
1. Introduction
Bradykinin (BK) is a nonapeptide formed by the action of
a serine protease called kallikrein. The kallikrein produces
kinins which are largely released into interstitial fluid, blood,
and glandular tissue, in particular by the pancreas. Several
studies have demonstrated the role of BK in the modulation
of important physiological eﬀects such as inflammation,
vascular permeability, hypotension, edema, smooth muscle
contraction, and glucose homeostasis, and most of these
actions are mediated by the B2 receptor (B2R) [1, 2].
Recently, some mechanisms have been proposed to ex-
plain the role of BK on glucose homeostasis. Studies have
reported that BK enhances the tyrosine phosphorylation of
IRS1 and thus improves the binding aﬃnity of IRS1 with
the P85 regulatory subunit of PI3K, which increases the
translocation of GLUT4 to the plasma membrane [3]. In
addition, the activation of endothelial nitric oxide synthase
(eNOS) by BK results in improved blood flow thereby
increasing glucose supply to peripheral tissues [4].
B1 or B2 receptors mediate the eﬀects of BK. It has been
accepted that almost all of the physiologically significant
eﬀects of BK, including the metabolic ones, are exerted by
activation of the B2R [5]. Based on this information, several
studies have focused on insertion/deletion polymorphism in
the exon 1 of the BK type 2 receptor gene (BDKRB2). The
presence (+9 bp) rather than the absence (−9 bp) of a 9-base
pair sequence was associated to lower gene transcriptional
activity [6, 7]. The main aim of this study was to evaluate
the association of the BDKRB2 +9/−9 polymorphism with
diabetes mellitus risk in the Brazilian general population.
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2. Methods
2.1. Study Population. This study included 1,032 subjects
of the general urban population selected from the Hearts
of Brazil Project (HBP). The design was a transversal and
multicenter observational cohort study. The universe of the
HBP consisted in the set of inhabitants of Brazilian urban
centers withmore than 100,000 inhabitants. TheHBP sample
plan was calculated as 2,500 interviews, distributed in 72
cities from the 5 regions of the country proportionally to
the number of inhabitants, per gender and age range, based
on data from IBGE (Brazilian Census). In the selected cities,
the “households” constituted the second-stage units, with
one interview per household. Subjects were separated in
self-declared “racial/color” subgroups, according to Brazilian
Census, as White, Intermediate (meaning Brown, Pardo
in Portuguese), or Black [8–10]. The study protocol was
approved by the involved Institutional Ethics Committees
and written informed consent was obtained from all partici-
pants prior to entering the study.
2.2. Anthropometrical, Blood Pressure, and Biochemical Data.
Weight, height, and waist were measured according to a
standard protocol. Body mass index (BMI) was calculated
and obesity defined as BMI ≥ 30 kg/m2. Blood pressure
was measured in the sitting position with the use of a
standard mercury sphygmomanometer on the left arm after
5 minutes’ rest. The first and fifth phases of Korotkoﬀ
sounds were used for systolic (SBP) and diastolic blood
pressure (DBP), respectively. Hypertension was defined as
mean SBP ≥ 140mmHg and/or DBP ≥ 90mmHg or use of
anti-hypertension drugs [11]. Fasting glucose, triglycerides
(TG), and total cholesterol (TC) were assayed by technology
point-of-care (Roche Diagnostics, Accu-Check). Diabetes
was defined as fasting glucose ≥ 126mg/dL or hypoglycemic
drugs use according to physician prescription (previous
diabetes) [12].
2.3. Genotyping. Genomic DNA was extracted from periph-
eral blood leukocytes following a salting-out method. Geno-
types for the BDKRB2+9/−9 bp insertion/deletion polymor-
phism was performed by polymerase chain reaction followed
by restriction fragment length polymorphism (PCR-RFLP)
as previously described [13]. Quality control for these assays
was assessed by randomly selecting 10% samples to be re-
genotyped by two independent technicians.
2.4. Statistical Analyses. Statistical analyses were carried out
using the SPSS 19.0 software (Chicago, IL, USA), with
the level of significance set at P ≤ 0.05. Categorical
variables were presented as percentage, whereas continuous
variables were presented as mean ± standard deviation.
Diﬀerences in the categorical and continuous parameters
according to genotypes for the BDKRB2 polymorphism were
tested by chi-square test and Student’s t-test, respectively.
Logistic regression analyses were performed to evaluate the
association of the BDKRB2 polymorphism with diabetes
mellitus plus adjustment for covariates.
3. Results
Demographic and clinical data of the studied population
samples are shown in Table 1. Genotypic frequencies were
26.8% for +9/+9; 53.4% for +9/−9; 19.8% for −9/−9,
and frequency of deletion allele was of 47%. Genotypic
distribution in the overall sample was in accordance with the
Hardy-Weinberg equilibrium (P = 0.46, χ2 = 0.54).
Diﬀerences in age, gender, race/color, BMI, obesity, ab-
dominal circumference, SBP, DBP, hypertension, TG, and TC
according to genotype groups were not observed (+9/+9 plus
+9/−9 versus−9/−9). However, individuals carrying +9/+9
or +9/−9 genotypes had higher glucose values (84.5mg/dL
versus 80.6mg/dL; P = 0.04, resp.) and higher frequency
of diabetes mellitus (7.6% versus 3.6%, resp.) compared to
individuals carrying −9/−9, adjusting for age, gender, and
BMI (Table 1). In addition, higher diabetes mellitus risk was
associated to presence of the +9/+9 or +9/−9 genotypes
(OR = 1.91; 95% CI = 1.09–4.19; P = 0.03) (Table 1).
4. Discussion
The main finding of this study was that the BDKRB2 +9/−9
polymorphism is associated with fasting glucose values and
with diabetes mellitus risk in the Brazilian population. These
genetic associations, although exploratory regarding casual
relations, may have a role in the generation of hypothesis to
be tested in more controlled studies.
In recent years, numerous studies have demonstrated the
important biological role of BK in the modulation of various
physiological conditions mediated through its binding to B1
and B2 receptors [1, 2]. In addition, a recent study reported
that the B2 receptor mediates the interaction of BK with
pathways related to glucose homeostasis [5].
Some investigations confirmed the key role of BK on
insulin sensitivity [14], glucose uptake [15], and insulin
secretion by beta cells [16]. Iozzo et al., studying obese and
lean individuals, demonstrated that intra-arterial infusion
of BK in the left leg resulted in an increase in glucose
uptake restricted to lean subjects [17]. Corroborating the
above results, Uehara et al. demonstrated that infusion of BK
increased glucose uptake into dog peripheral tissues and that
infusion of a BK antagonist abolished this eﬀect on insulin
sensitivity [18].
Finally, Yang andHsu, studying rat pancreas, showed that
the infusion of BK increased the insulin release by beta cells.
Furthermore, the BK optimized insulin release stimulated by
glucose [16]. In this scenario and knowing that the presence
(+9 bp) rather than the absence (−9 bp) of a 9-base pair
sequence was associated to lower gene transcriptional activity
[6, 7], our results suggest a role of BK on glucose homeostasis
represented by increased risk for diabetes mellitus.
Considering the pivotal role of B2 receptor in the physi-
ological actions of BK, studies evaluating this genetic variant
with metabolic phenotypes are still scarce in the literature.
Our findings are supported by functional studies in the
literature [14–17]. Moreover, previous studies demonstrated
the role of the B2 receptor in the metabolic actions of BK
[5] and association of BDKRB2 +9 allele with lower gene
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Table 1: Demographic, clinical, and biochemical data according to genotypes for the BDKRB2 polymorphism.
Subject Characteristics +9/+9 /+9/−9 −9/−9
P value
n, (%) 845 (80.2%) 208 (19.8%)
Gender, male 386 (45.7%) 99 (47.6%) 0.62
Ethnicity, n (%)
African descent 81 (9.6%) 17 (8.2%)
0.63Caucasian descent 493 (58.3%) 126 (60.6%)
Mullato 256 (30.3%) 59 (28.4%)
Others 15 (1.8%) 6 (2.9%)
Diabetes, n (%) 64 (7.6%) 8 (3.6%) 0.03
Obesity, n (%) 183 (24.4%) 41 (21.6%) 0.41
Age, years 42.7 ± 14.1 44.4 ± 15.2 0.12
BMl∗, kg/m2 27.0 ± 5.1 26.4 ± 4.8 0.19
Abdominal Circumference, cm 90.5 ± 13.6 90.4 ± 13.3 0.90
SBP†, mmHg 128.6 ± 23.4 126.2 ± 22.1 0.13
DBP†, mmHg 80.1 ± 14.3 78.4 ± 12.4 0.07
Glucose†, mg/dL 84.5 ± 28.3 80.6 ± 21.9 0.04
Triglycerides†, mg/dL 154.2 ± 86.4 146.9 ± 71.2 0.33
Total cholesterol†, mg/dL 193.4 ± 35.4 187.7 ± 33.2 0.13
OR [95% CI], P value
Diabetes Mellitus
Unadjusted Adjusted†
Genetic Models of Inheritance
+9/+9/+9/−9 genotype group
2.05 [0.97–4.34] 1.91 [1.09–4.19]
0.06 0.03
∗
Adjusted for gender and age.
†Adjusted for gender, age, and BMI.
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure.
“Race/color” was classified according to Brazilian Census as White, Intermediate (meaning Brown, Pardo in Portuguese), or Black.
transcriptional activity [7]. Finally, our data may suggest
that the reduced transcriptional activity of the B2 receptor
presented by +9 allele carriers is associated to lower BK
activity, reduced glucose uptake [15], and insulin resistance
[14]. Thus, it could generate an unfavorable glucose profile
and consequent increased risk for developing diabetes.
There are some limitations in our study. First, we were
not able to specifically determine the molecular alteration
responsible for the observed association. Nonetheless, in
the described scenario, our data plus literature data are
well grounded and provide evidence that the BDKRB2
gene may constitute not only a link between biomechanical
transduction and diabetes condition, but may also be a
fundamental gateway for both epidemiological and mech-
anistic studies involving diabetes, hypertension, and renin-
angiotensin system hyperactivity. Second, our examination
of glucose has its limitations against the gold standard.
However, the classification of the diabetes condition was
made according to criteria recommended [12]. Finally, it is
not possible to completely exclude the interaction between
the use of other genetic markers, ethnicity, concomitant
drugs, and other covariates on our findings [19, 20].
In conclusion, our data suggest that the BDKRB2 +9/−9
polymorphism may act as a genetic modulator of glucose
homeostasis. It was previously associated to insulin sensi-
tivity [14], glucose uptake [15], and insulin secretion by
beta cells [16] and, in this study, data suggest that the poly-
morphism may increase susceptibility to chronic metabolic
conditions such as diabetes in the Brazilian population.
Conflict of Interests
The authors declare that they have no conflict of interests.
Acknowledgments
P. C. J. L. Santos is recipient of the fellowship from FAPESP,
Proc. 2010-17465-8, Brazil. The technical assistance of the
Laboratory of Genetics and Molecular Cardiology group,
Heart Institute group, and Samaritano Hospital is gratefully
acknowledged.
References
[1] D. Regoli and J. Barabe´, “Pharmacology of bradykinin and
related kinins,” Pharmacological Reviews, vol. 32, no. 1, pp. 1–
46, 1980.
[2] E. S. M. Rocha, W. T. Beraldo, and G. Rosenfeld, “Bradykinin,
a hypotensive and smooth muscle stimulating factor released
from plasma globulin by snake venoms and by trypsin,”
American Journal of Physiology, vol. 156, pp. 261–273, 1949.
4 Experimental Diabetes Research
[3] T. Shiuchi, T. X. Cui, L. Wu et al., “ACE inhibitor improves
insulin resistance in diabetic mouse via bradykinin and NO,”
Hypertension, vol. 40, no. 3, pp. 329–334, 2002.
[4] H. Beck-Nielsen and L. C. Groop, “Metabolic and genetic
characterization of prediabetic states. Sequence of events
leading to non-insulin-dependent diabetes mellitus,” Journal
of Clinical Investigation, vol. 94, no. 5, pp. 1714–1721, 1994.
[5] I. Duka, S. Shenouda, C. Johns, E. Kintsurashvili, I. Gavras,
and H. Gavras, “Role of the B2 receptor of bradykinin in
insulin sensitivity,”Hypertension, vol. 38, no. 6, pp. 1355–1360,
2001.
[6] A. Braun, S. Kammerer, E.Maier, E. Bo¨hme, and A. A. Ro¨scher,
“Polymorphisms in the gene for the human B2-bradykinin
receptor. New tools in assessing a genetic risk for bradykinin-
associated diseases,” Immunopharmacology, vol. 33, no. 1–3,
pp. 32–35, 1996.
[7] C. C. Lung, E. K. L. Chan, and B. L. Zuraw, “Analysis of an
exon 1 polymorphism of the B2 bradykinin receptor gene and
its transcript in normal subjects and patients with C1 inhibitor
deficiency,” Journal of Allergy and Clinical Immunology, vol. 99,
no. 1 I, pp. 134–146, 1997.
[8] M. Makdisse, A. D. C. Pereira, D. D. P. Brasil et al., “Prevalence
and risk factors associated with peripheral arterial disease in
the hearts of Brazil project,” Arquivos Brasileiros de Cardiolo-
gia, vol. 91, no. 6, pp. 370–414, 2008.
[9] P. C. J. L. Santos, R. A. G. Soares, D. B. G. Santos et al.,
“CYP2C19 and ABCB1 gene polymorphisms are diﬀerently
distributed according to ethnicity in the Brazilian general
population,” BMC Medical Genetics, vol. 19, no. 12, article 13,
2011.
[10] R. A. G. Soares, P. C. J. L. Santos, G. L. L. MacHado-Coelho
et al., “CYP2C9 and VKORC1 polymorphisms are diﬀerently
distributed in the brazilian population according to self-
declared ethnicity or genetic ancestry,” Genetic Testing and
Molecular Biomarkers, vol. 16, no. 8, pp. 957–963, 2012.
[11] “1999 World Health Organization-International Society of
Hypertension Guidelines for the Management of Hyperten-
sion. Guidelines Subcommittee.,” Journal of Hypertension, vol.
17, no. 2, pp. 151–183, 1999.
[12] “Executive summary: standards of medical care in diabetes—
2011,” Diabetes Care, vol. 34, supplement1, pp. S4–S10, 2011.
[13] S. Kammerer, A. Braun, N. Arnold, and A. A. Roscher, “The
human bradykinin B2 receptor gene: full length cDNA,
genomic organization and identification of the regulatory
region,” Biochemical and Biophysical Research Communica-
tions, vol. 211, no. 1, pp. 226–233, 1995.
[14] E. J. Henriksen, S. Jacob, H. J. Augustin, and G. J. Dietze, “Glu-
cose transport activity in insulin-resistant rat muscle: eﬀects
of angiotensin-converting enzyme inhibitors and bradykinin
antagonism,” Diabetes, vol. 45, no. 1, pp. S125–S128, 1996.
[15] G. Doetze and M. Wicklmayr, “Evidence for a participation
of the kallikrein kinin system in the regulation of muscle
metabolism during muscular work,” FEBS Letters, vol. 74, no.
2, pp. 205–208, 1977.
[16] C. Yang and W. H. Hsu, “Stimulatory eﬀect of bradykinin
on insulin release from the perfused rat pancreas,” American
Journal of Physiology, vol. 268, no. 5, pp. E1027–E1030, 1995.
[17] P. Iozzo, A. Viljanen, M. A. Guzzardi et al., “The interaction
of blood flow, insulin, and bradykinin in regulating glucose
uptake in lower-body adipose tissue in lean and obese
subjects,” Journal of Clinical Endocrinology and Metabolism,
vol. 97, no. 7, pp. E1192–E1196, 2012.
[18] M. Uehara, H. Kishikawa, S. Isami et al., “Eﬀect on insulin
sensitivity of angiotensin converting enzyme inhibitors with
or without a sulphydryl group: bradykinin may improve
insulin resistance in dogs and humans,” Diabetologia, vol. 37,
no. 3, pp. 300–307, 1994.
[19] R. O. Alvim, P. C. J. L. Santos, N. E. Ferreira, J. G. Mill, J. E.
Krieger, and A. C. Pereira, “Thioredoxin interacting protein
(TXNIP) rs7212 polymorphism is associated with arterial
stiﬀness in the Brazilian general population,” Journal of
Human Hypertension, vol. 26, no. 5, pp. 340–342, 2012.
[20] P. C. J. De Lima Santos, R. De Oliveira Alvim, N. E. Ferreira et
al., “Ethnicity and arterial stiﬀness in Brazil,”American Journal
of Hypertension, vol. 24, no. 3, pp. 278–284, 2011.
